LENZ Therapeutics (LENZ) Stock Price, News & Analysis

Company Overview

LENZ Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing ophthalmic medicines for people with presbyopia, an age-related condition that reduces the eye’s ability to focus on near objects. The company’s lead product is VIZZ (aceclidine hydrochloride ophthalmic solution), a prescription eye drop designed to improve near vision by creating a pinhole effect through pupil modulation while aiming to preserve distance vision.

In July 2025, the U.S. Food and Drug Administration approved VIZZ for the treatment of presbyopia in adults. The approval marked the company’s transition from a clinical-stage developer to a commercial ophthalmology company. LENZ is focused on making VIZZ available to patients and eye-care professionals in the United States and may pursue additional regulatory and commercial opportunities in other geographies.

LENZ Therapeutics was established to address unmet needs in the treatment of presbyopia and is headquartered in San Diego, California. The company is led by Chief Executive Officer Eef Schimmelpennink, who has experience in the pharmaceutical and ophthalmology industries. Its shares trade on the Nasdaq under the symbol LENZ.

Key Stats

• Today's Range: $3.79 to $3.97
• 50-Day Range: $3.72 to $5.96
• 52-Week Range: $3.60 to $50.40
• Volume: 644,853 shs
• Average Volume: 912,112 shs
• Market Capitalization: $121.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $28.80
• Consensus Rating: Moderate Buy

LENZ Therapeutics Stock Analysis - MarketRank™

LENZ Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 382nd out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

LENZ Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

LENZ Therapeutics has a consensus price target of $28.80, representing about 639.4% upside from its current price of $3.90.

Amount of Analyst Coverage

LENZ Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for LENZ Therapeutics are expected to grow in the coming year, from ($4.18) to ($3.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of LENZ Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of LENZ Therapeutics is -0.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

LENZ Therapeutics has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

36.89% of the float of LENZ Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

LENZ Therapeutics has a short interest ratio ("days to cover") of 14.55, which indicates bearish sentiment.

Change versus previous month

Short interest in LENZ Therapeutics has recently decreased by 2.25%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

LENZ Therapeutics does not currently pay a dividend.

Dividend Growth

LENZ Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.22

News Sentiment

LENZ Therapeutics has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for LENZ Therapeutics this week, compared to 4 articles on an average week.

Search Interest

Only 1 people have searched for LENZ on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.30% of the stock of LENZ Therapeutics is held by insiders.

Percentage Held by Institutions

54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:LENZ
• Previous Symbol: NASDAQ:LENZ
• CIK: 1815776
• Web: www.lenz-tx.com
• Phone: (858) 925-7000
• Fax: N/A
• Employees: 152
• Year Founded: 2013

Price Target and Rating

• Average Price Target for LENZ Therapeutics: $28.80
• High Price Target: $50.00
• Low Price Target: $7.00
• Potential Upside/Downside: +646.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.09)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$82.13 million
• Net Margins: -586.74%
• Pretax Margin: -586.72%
• Return on Equity: -53.39%
• Return on Assets: -49.14%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 13.55
• Quick Ratio: 13.31

Sales & Book Value

• Annual Sales: $19.09 million
• Price / Sales: 6.35
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.09 per share
• Price / Book: 0.42

Miscellaneous

• Outstanding Shares: 31,420,000
• Free Float: 28,812,000
• Market Cap: $121.28 million
• Optionable: N/A
• Beta: 0.66